Experimental One-Dose Treatment Cuts ‘Bad’ Cholesterol by 52% in First Human Trial

Image credit: Brgfx via Magnific. Article by David Nield. ScienceAlert – September 4, 2026. Research article: New England Journal of Medicine.

Too much ‘bad’ cholesterol in the bloodstream – that’s the low-density lipoprotein (LDL) type – can contribute to plaque buildup in the arteries, increasing the risk of cardiovascular problems like heart attacks and strokes. Many factors affect LDL cholesterol levels, including genetics, diet, and age, while treatments for high cholesterol can involve dietary changes and statins. Scientists are now working on a precise DNA-editing approach, using CRISPR technology to make a permanent genetic change that could durably reduce LDL cholesterol after a single treatment. Called CTX310, it aims to mimic a naturally occurring genetic variant that lowers LDL cholesterol via reduced expression of a liver protein called ANGPTL3. […]

Click here to view original web page at www.sciencealert.com

Video: CRISPR Explained – Mayo Clinic